Janus Henderson Group PLC Has $414.78 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

Janus Henderson Group PLC lifted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 54.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,483,999 shares of the company's stock after purchasing an additional 3,346,755 shares during the quarter. Janus Henderson Group PLC owned approximately 5.64% of Revolution Medicines worth $414,777,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of RVMD. Vanguard Group Inc. lifted its position in Revolution Medicines by 14.7% during the 4th quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock worth $747,799,000 after acquiring an additional 2,185,082 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Revolution Medicines by 17.1% in the fourth quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock worth $579,498,000 after purchasing an additional 1,931,000 shares during the period. Baker BROS. Advisors LP increased its stake in shares of Revolution Medicines by 4.9% in the fourth quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock worth $347,163,000 after purchasing an additional 367,882 shares during the period. FMR LLC lifted its position in shares of Revolution Medicines by 14.7% during the 4th quarter. FMR LLC now owns 6,742,083 shares of the company's stock worth $294,899,000 after purchasing an additional 866,190 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Revolution Medicines by 10.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,865,962 shares of the company's stock valued at $256,578,000 after purchasing an additional 552,657 shares during the period. Institutional investors own 94.34% of the company's stock.

Insiders Place Their Bets

In other news, CFO Jack Anders sold 1,864 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $72,770.56. Following the completion of the transaction, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at approximately $4,489,834.24. This represents a 1.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Margaret A. Horn sold 3,058 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $119,384.32. Following the completion of the sale, the chief operating officer now directly owns 153,533 shares in the company, valued at approximately $5,993,928.32. This represents a 1.95% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock worth $650,406 over the last quarter. Company insiders own 8.20% of the company's stock.

Revolution Medicines Stock Down 0.1%

Revolution Medicines stock traded down $0.04 on Thursday, hitting $39.44. The company's stock had a trading volume of 899,044 shares, compared to its average volume of 1,491,953. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $62.40. The firm has a market cap of $7.35 billion, a P/E ratio of -10.99 and a beta of 1.11. The company has a fifty day moving average price of $37.42 and a 200-day moving average price of $43.31.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same quarter last year, the business posted ($0.70) EPS. Analysts anticipate that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Wall Street Analysts Forecast Growth

RVMD has been the topic of several recent analyst reports. Stifel Nicolaus dropped their price target on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Wedbush reaffirmed an "outperform" rating and set a $67.00 target price on shares of Revolution Medicines in a research report on Thursday, May 8th. Oppenheimer increased their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and issued a $57.00 price target on shares of Revolution Medicines in a research report on Thursday, May 8th. Finally, Guggenheim dropped their price objective on shares of Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $67.08.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.